HIMS Stock On Track To Fall For The First Time In Seven Sessions – Why Is Amazon’s GLP-1 Program In The Spotlight?

• Amazon said its GLP-1 medications are available for fast delivery across all 50 states, with same-day delivery currently offered in nearly 3,000 cities and towns.
• Amazon will offer GLP-1 drugs with insurance plans starting at $25 per month and cash-pay options from $149 per month.
• HIMS has been in the spotlight after the FDA signalled openness in allowing compounding pharmacies to produce certain peptides.

Hims & Hers Health Inc. (HIMS) came under the spotlight on Tuesday, after Amazon.com Inc. (AMZN) launched a comprehensive GLP-1 management program through Amazon One Medical, combining primary care, pharmacy services, and virtual care options.

HIMS stock fell around 4% at the time of writing, on track to end a six-session winning streak that had lifted the stock nearly 60%.

Fast Delivery Across Nearly 3,000 Cities And Towns

Amazon will offer the United States Food and Drug Administration (FDA)- approved Wegovy and Foundayo oral GLP-1 pills for weight management, with insurance plans starting at $25 per month and cash-pay options starting at $149 per month for both drugs.

The GLP-1 management program includes screenings, consultations, and regular follow-ups to help manage obesity and related conditions such as heart disease and diabetes.

Amazon said its GLP-1 medications are available for fast delivery across all 50 states, with same-day delivery currently offered in nearly 3,000 cities and towns. The company plans to expand delivery to around 4,500 cities and towns by the end of 2026.

Last month, the telehealth firm launched a broad lineup of GLP-1 drugs from Novo Nordisk (NVO), including Wegovy. The rollout came shortly after Novo dropped a patent infringement lawsuit tied to Hims’ low-cost compounded version of the drug.

HIMS’ Peptide Boost

HIMS has been in the spotlight recently after the FDA signalled openness to allowing compounding pharmacies to produce certain peptides. The agency is considering removing 12 peptides from a high-risk category, a move Leerink analyst Michael Cherny views as a positive for the company.

The potential rule change could support growth as the company shifts to commercial weight-loss products and expands the use of its existing peptide facility, Cherny said, according to The Fly.

How Did Retail Traders React?

Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.

Many users dismissed Amazon’s GLP-1 news as a potential trigger for the intraday slide in HIMS stock.

One user said that Amazon’s scale, logistics, and pricing leverage are hard to ignore.

Year-to-date, the stock has shed around 13%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.